Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.48 |
| ▸ | F10 | P00742 | 7/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623772 | 0.94 | F7 (0.47) | SLC6A9SLC6A5F10F2F7 | |
| SCHEMBL1624584 | 0.82 | HDAC1 (0.47) | F10F2F7PRSS1CYP2C9 | |
| SCHEMBL1625260 | 0.80 | F10 (0.42) | F10F2PRSS1PLAUITGB3 | |
| SCHEMBL1624466 | 0.80 | ST14 (0.46) | F10F2PRSS1 | |
| SCHEMBL1626370 | 0.78 | HPGDS (0.50) | F10F2PRSS1 | |
| SCHEMBL1625575 | 0.77 | F7 (0.52) | F10F2F7 | |
| SCHEMBL1625707 | 0.77 | F2 (0.53) | F10F2F7PRSS1PLAU | |
| SCHEMBL1624480 | 0.76 | GAA (0.45) | F10F2F7PRSS1PLAU | |
| SCHEMBL1625271 | 0.75 | PLAU (0.44) | F10F2F7PRSS1CYP2C9 | |
| SCHEMBL1623719 | 0.74 | NPSR1 (0.44) | F10F2PRSS1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | SLC6A9 2132/4885SLC6A5 2274/4885F10 378/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | SLC6A9 1580/4885SLC6A5 1688/4885F10 292/4885 |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | SLC6A9 2132/4885SLC6A5 2274/4885F10 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.